NAD⁺ biology and supplementation: From mechanisms to clinical perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review and mathematical modeling without new primary clinical trial data
PubMed 42489969 · doi:10.1007/s11033-026-12351-3
What was done
Combined a literature review with mathematical modeling to assess the biological mechanisms, pharmacodynamics, and clinical perspectives of oral NAD⁺ precursors (nicotinamide riboside and nicotinamide mononucleotide) and intravenous NAD⁺ administration.
What was found
The abstract reports no numerical data. It qualitatively notes that oral precursors increase circulating NAD⁺ levels with context-dependent clinical benefits, intravenous NAD⁺ remains poorly validated, and mathematical modeling demonstrates non-linear kinetics influenced by dose, age, baseline metabolic state, feedback loops, and biological saturation.
Why it matters
Explains why clinical trial results for NAD⁺ precursors have been heterogeneous by demonstrating that NAD⁺ metabolism behaves as a non-linear, saturated regulatory system rather than a simple dose-response relationship.
Limits
This is a narrative review and theoretical modeling paper rather than a primary clinical trial or systematic meta-analysis. The abstract provides no quantitative parameters, sample size of reviewed studies, or empirical validation metrics.
Cited by
- context Direct oral ingestion of pure NAD+ has poor cellular bioavailability compared to oral precursor supplementation or intravenous NAD+ infusion.